We have located links that may give you full text access.
Evaluation of hemocompatibility and hemostasis of a bioflocculant.
Colloids and Surfaces. B, Biointerfaces 2017 November 2
Bioflocculants are widely used in a large variety of applications, because of their wide range of flocculation. There is limited information in the literature about the ability of bioflocculants to perform beneficial functions without having adverse effects on blood components. In this study, general hemocompatibility of a bioflocculant (MBF-06) was investigated in an in vitro system, measuring flocculation of plasma proteins, red blood cell integrity, blood cell counts, platelet activation, clot formation, complement activation, cytotoxicity and inflammatory response. Effects of MBF-06 included low plasma protein flocculation, low platelet activation, low inflammatory response, no hemolysis or cytotoxicity and increased expression of coagulation markers, including prothrombin fragments 1+2. These findings suggested that the rapid hemostasis caused by MBF-06 resulted, essentially, from humoral coagulation. Overall, our observations revealed the great potential of MBF-06 as a novel hemostatic agent.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app